<Back to Therapeutic Areas

<Back to Menu

Respiratory

IME/CME for HCPs

GSK identifies and funds innovative, high-quality, independent third-party educational initiatives that are designed to close healthcare professional (HCP) educational, quality, and performance gaps to improve patient health and quality of life. GSK provides financial support for independent medical education (IME) for HCPs, including certified continuing medical education (CME, CE), with a grant.

Educational providers are fully compliant with the ACCME (and other nationally recognized accrediting body) standards for commercial support and design and deliver all activities (including content, faculty, speakers, and educational materials) independent from GSK control, influence, and involvement.

These initiatives offer opportunities for continual learning regarding educational topics and are free for learners to access. For more information about any of these initiatives, please click the link to be directed to the educational provider's website. All questions about these activities should be directed to the educational provider listed for each activity, not to GSK, as these are not GSK initiatives.


Hypereosinophilic Syndrome

D is for Diagnosis Rare Disorders Respiratory

Expiration Date: November 30, 2022

Educational Provider: Physicians’ Education Resource, LLC


Chronic Rhinosinusitis with Nasal Polyps

Novel Therapies for Chronic Rhinosinusitis with Nasal Polyps

Expiration Date: December 10, 2022

Educational Provider: University of Cincinnati


New Biologics Agents in CRSwNP

Expiration Date: May 2, 2023

Educational Provider: Integrity Continuing Education, Inc.


GSK Medical will be attending the following key congresses. Please visit us at our scientific booth or view our scientific information.

Meet Us

AAAAI | Feb 24-27, 2023 | San Antonio, TX

ATS | May 19-24, 2023 | Washington, DC

AAOA | Sep 28-30, 2023 | Nashville, TN

CHEST | Oct 8-11, 2023 | Honolulu, HI

AAFP | Oct 26-29, 2023 | Chicago, IL

ACAAI | Nov 9-13, 2023 | Anaheim, CA

View our ongoing, innovative research with respiratory diseases.

ASTHMA Phase I Phase II Phase III

SWIFT 1: Placebo-Controlled Efficacy and Safety Study of Depemokimab in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04719832

SWIFT 2: A Study of Depemokimab in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718103

NIMBLE: A Study of Depemokimab Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718389

An Open-Label Extension Study of Depemokimab in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

NCT05243680
COPD Phase I Phase II Phase III

MATINEE: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

NCT04133909
EGPA Phase I Phase II Phase III

Longitudinal Study for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)

NCT00315380
(Observational)

OCEAN: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory EGPA

NCT05263934
HYPEREOSINOPHILIC SYNDROME Phase I Phase II Phase III

SPHERE: Study in Pediatrics With HypEREosinophilic Syndrome

NCT04965636

DESTINY: Depemokimab in Participants With HES, Efficacy, and Safety Trial

NCT05334368
CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS Phase I Phase II Phase III

ANCHOR-1: Efficacy and Safety of Depemokimab in Participants with CRSwNP

NCT05274750

ANCHOR-2: Efficacy and Safety of Depemokimab in Participants with CRSwNP

NCT05281523
PHARMACOKINETIC STUDY Phase I Phase II Phase III

A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

NCT05602025

View information about our respiratory portfolio of products including prescribing information, and material safety sheets.

ADVAIR DISKUS

(fluticasone propionate and salmeterol inhalation powder)

Material Safety Data Sheets Environmental Risk Assessments

ADVAIR HFA

(fluticasone propionate and salmeterol inhalation aerosol)

Material Safety Data Sheets Environmental Risk Assessments

ANORO ELLIPTA

(umeclidinium and vilanterol inhalation powder)

Material Safety Data Sheets Environmental Risk Assessments

ARNUITY ELLIPTA

(fluticasone furoate inhalation powder)

Material Safety Data Sheets Environmental Risk Assessments

BECONASE AQ

(beclomethasone dipropionate, monohydrate) Nasal Spray

Material Safety Data Sheets Environmental Risk Assessments

BREO ELLIPTA

(fluticasone furoate and vilanterol inhalation powder)

Material Safety Data Sheets Environmental Risk Assessments

FLOVENT DISKUS

(fluticasone propionate inhalation powder)

Material Safety Data Sheets Environmental Risk Assessments

FLOVENT HFA

(fluticasone propionate inhalation aerosol)

Material Safety Data Sheets Environmental Risk Assessments

TRELEGY ELLIPTA

(fluticasone furoate, umeclidinium, and vilanterol inhalation powder)

Material Safety Data Sheets Environmental Risk Assessments

Please see below for disease state videos, and webinars related to respiratory illnesses.

COPD

Patients Presenting with Dyspnea With Dr. Vega (4:42 duration)

© American Academy of Family Physicians 2021. All rights reserved.

Assessment of Patient Presenting With Dyspnea With Dr. Vega (4:18 duration)

© American Academy of Family Physicians 2021. All rights reserved.

Patient Presenting with Recent Exacerbations with Dr. Skolnik (4:03 duration)

© American Academy of Family Physicians 2021. All rights reserved.

Assessment of a Patient Presenting with Recent Exacerbations with Dr. Skolnik (9:29 duration)

© American Academy of Family Physicians 2021. All rights reserved.

Intervention Opportunities in COPD Management Infographic

© American Academy of Family Physicians 2021. All rights reserved.

COPDetective Interactive Game


Asthma

Role of LAMAs in Asthma With Dr. Spahn (6:12)


The Role of Eosinophils and Their Potential Heterogeneity in Airways Disease (50:00)

Asthma Ascent Escape Room Game
(An Interactive Game)

Clinical Profiles in Severe Eosinophilic Asthma (60:58)

EGPA

EGPA: Pathogenesis, Diagnosis, and Management With Dr. Wechsler (28:06)

EGPA Mechanism of Disease (3:54)

HES

Investigating the Role of Eosinophils in Health, Airway Diseases, and Hypereosinophilic Disorders (40:56)

Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease (19:53)

HES Mechanism of Disease (6:24)

CRSwNP

Chronic Rhinosinusitis and Comorbid Conditions: Update on Etiology and Treatment (43:25)

Chronic Rhinosinusitis, Nasal Polyps and Asthma: The Unified Airway (50:20)

Revealing Key Pathophysiology to Guide Future Management of CRS/CRSwNP (53:25)

GSK Respiratory Medical Team attends several key medical congresses. You can access presentations, posters, and symposia material below.

ACAAI 2022

November 10-14, 2022 | Louisville, KY

ACR 2022

November 10-14, 2022 | Philadelphia, PA

CHEST 2022

October 16-19, 2022 | Nashville, TN

ATS 2022

May 13-18, 2022 | San Francisco, CA

AAAAI 2022

Feb 25–28, 2022 | Phoenix, AZ

Please see below for disease state audio podcasts related to respiratory illnesses.

Uncontrolled Asthma: Unmet Needs With Dr. Ditto (21:44)

Uncontrolled Asthma: Putting Guidelines into Practice With Dr. Ditto (19:18)

Uncontrolled Asthma: Unmet Need With Drs. Soler and Hannania (12:30)

Uncontrolled Asthma: Practical Considerations for Primary Care With Ditto (22:03)

A Look at Diagnostic Challenges for severe Asthma (11:29)

Obstacles of diagnosing severe and/or uncontrolled asthma (reachmd.com)

Evaluating Eosinophilic Disorders: EGPA & HES (13:59)

How to better distinguish between EGPA and HES. (reachmd.com)